Cell and gene therapy (CGT), including chimeric antigen receptor (CAR) T-cell therapy represents a new frontier in the fight against rare genetic disorders and cancers. 

Complex study designs, challenging patient populations and distinct operational delivery requirements are the norm in CGT clinical trials. New treatment approaches are often unfamiliar to investigators, site staff and patients. 

The Syneos Health Cell and Gene Therapy Development Engine, built upon nearly two decades of experience in the field, is the hub for our knowledge and experience in CGT preclinical/clinical development and commercialization, including CAR-T trials. It brings together the cross-functional capabilities needed to navigate the challenges unique to cell therapy trials, accelerate their development and deliver on their promise. 


Meet with us at the 6th Annual CAR-TRC Summit to discuss your CAR-T development or commercialization challenge. 


Book a Meeting



Understanding the value in patient perceived experience and tolerance in CAR-T treatment​

Wednesday, February 22: 5:30 p.m.







Anthony (AJ) Messina, Ph.D.(c), MSHS, CCRP, Director, Assessment & Insight, Insights Gathering, Syneos Health

Want to learn more? Explore Insights Hub

or click on the resources below:

Insights Gathering Patient Voice CAR-T Syneos Health


Tue, Feb 21, 07:00 am to Thu, Feb 23, 07:00 pm
ExCel London
Western Gateway
E16 1AL Greater London, England
United Kingdom
View Map
Additional Details 

Platinum Suite, ExCel London 
Royal Victoria Dock, 1 Western Gateway,
London, E16 1XL, United Kingdom